Ignite Creation Date:
2025-12-24 @ 4:14 PM
Ignite Modification Date:
2025-12-24 @ 4:14 PM
Study NCT ID:
NCT04218266
Status:
COMPLETED
Last Update Posted:
2022-10-27
First Post:
2020-01-02
Is Possible Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
Sponsor:
Bayer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-01-30
Start Date Type:
ACTUAL
Primary Completion Date:
2021-10-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-10-08
Completion Date Type:
ACTUAL
First Submit Date:
2020-01-02
First Submit QC Date:
None
Study First Post Date:
2020-01-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-09-19
Results First Submit QC Date:
None
Results First Post Date:
2022-10-27
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-10-26
Last Update Post Date:
2022-10-27
Last Update Post Date Type:
ACTUAL